Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DNDN merger a possibility?
This is a good possibility. John Johnson, CEO of DNDN in chairman of the board of TZYM. They could gobble this up for $1.50 per share in a stock swop, get the current cash and future BMS installment of 1.6M which I estimate at .63 and get Match for a net cost of .87 cents. They would then own the rights to any future $80M BMS milestones and have the technology for their own R & D . Be nice to see a bidding war here betwnn them and BMS. Just saying.
Really? Looks to me like it's up.
Some would like to buy at that level, although, it's not going to happen. It's worth at least .60 cash if you consider the R & D expenses are reduced to zero and add in the 1.6M BMS payment. Good luck to him though.
Ah, but it won't. More like a reversal coming. Back to .55 imo. Good luck.
I don't think so. Read my post #1544 for some valuable information that may point to some upward movement in the pps on Monday.
Totally agree with you here sunspotter. If we do some simple math, the cash on hand as of 12/31 was 15.3M. If we add in the 1.6M BMS payment for the 1Q and deduct approximately 1.2 admin expense for the 1Q, that should put us at 15.7M cash at the end of 1Q, assuming that there were no R & D expenses in 1Q. With 27.6M shares O/S, the pps just using cash alone should be .568 which is 29% higher than the .44 close yesterday. BMS has one more installment of 1.6M for the 2Q, so if you add that in the pps cash would be .628. Even if you didn't add any value at all for MATCH, or any future milestones possibilities from BMS, we are still way undervalued IMO. TZYM could be bought by BMS today for .628 and break even on cash alone and get MATCH for free and avoid any future milestones, so the way I see it .628 is a 42.7% gain from where we are today. Barring any unforseen suprises I think we are pretty safe at these levels. I think another possibility would be a merger with BMS or DNDN who may be interested in the technology. John Johnson, C.O.B. of TZYM is the CEO of DNDN. We'll see how it plays out in the future, will definately be interesting.
Or, it could mean .60
Agreed, hopefully a reversal here back up to .60 next week.
That would be nice!
Looks like someone is adding more at .44 in some very big buys, although, the mm dops it back down to .43 in 100 share sells. That seems criminal.
That boat may have already sailed, but you may get lucky. GL
Just a waiting game from here. Week hands that need lunch money get shook out on fear. None of the insiders have sold and it's trading below cash which I estimate at .503 at the end of the 1st quarter. Add MATCH value in, furniture, and the bologna sandwich in the fridge and you still have a bargain here. Pretty much a safe bet unless the CEO goes to the casino and tries to double down with the 15M in the bank.
I really doubt it since cash is .503 per share but good luck to you.
3/10 of 1% of OS shares traded yesterday. Low volume means no sellers. Waiting for the 3 to five bagger here. Could happen any time.
44,000 buys and 43,000 sells
Nobody selling, just waiting for buyout news now. If it's announced, you will see 10M shares traded before noon.
"The company does not intend to comment further regarding this process"
RESEARCH TRIANGLE PARK, N.C., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Tranzyme, Inc. (Nasdaq:TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other transaction to maximize value to its stockholders.
The Company has not made a decision to pursue any specific transaction or other strategic alternative, and there is no set timetable for the strategic review process. There can be no assurance that the exploration of strategic alternatives will result in the identification or consummation of any transaction. The Company does not intend to comment further regarding this process until such time as its Board of Directors has determined the outcome of the process or otherwise has deemed that disclosure is required or appropriate.
The Company has retained Stifel as its financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP as its legal counsel to assist with the strategic review process.
Alex Zisson has served as one of our directors since May 2005. Since 2002, Mr. Zisson has been a Partner at Thomas, McNerney & Partners, a prominent health care venture capital firm that invests in life science and medical technology companies at all stages of development. He is currently a board member of several private life sciences companies, including Clarus Therapeutics, Inc, and Celator Pharmaceuticals, Inc. Before joining Thomas, McNerney & Partners, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Mr. Zisson led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Mr. Zisson also became the firm's Health Care Strategist. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa. Mr. Zisson serves on the board of directors of numerous life sciences companies, has extensive knowledge of the health care and biopharmaceutical industries and has been instrumental in our development since joining our board in 2005.
Anne M. VanLent has served as one of our directors since March 2011. Ms. VanLent is currently the President of AMV Advisors, a company which she founded in 2008 to provide corporate strategy and financial consulting services to emerging growth life sciences companies. From May 2002 through April 2008, Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a company that develops and markets prescription dermatology products that was publicly-traded before being acquired by Stiefel Laboratories in June 2008. From July 1997 to October 2001, she was the Executive Vice President—Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993, she served as the Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. Ms. VanLent also currently serves as a director of and chair of the audit committee of Integra Life Sciences Holding Corporation (NasdaqGS: IART). She also served as a director of Penwest Pharmaceuticals, a NASDAQ-listed company from 1997 through its sale to Endo Pharmaceuticals, Inc. in the fall of 2010. Ms. VanLent received a B.A. degree in Physics from Mount Holyoke College. Ms. VanLent brings significant management experience in both public and private life sciences companies as well as expertise in financial and accounting matters that will enable her to serve as our audit committee financial expert.
Dr. Garg has served as President and Chief Executive Officer since September 2000 and as one of Tranzyme's directors since October 2000. Prior to joining Tranzyme, he served as Chief Operating Officer of Apex Bioscience, Inc. (now Curacyte AG of Munich, Germany), where he was responsible for establishing a major strategic alliance with a Japanese pharmaceutical company and advancing the company's lead product into Phase 2 clinical development. Earlier he was Vice President of Product Development and Manufacturing at DNX, Inc. (NASDAQ: DNXX), and held management positions at Sunovion Pharmaceuticals, Inc. (formerly known as Sepracor Inc.) (acquired by Dainippon Sumitomo Pharma) and Bio-Response Inc. (acquired by Baxter International, Inc.).
Jean-Paul Castaigne, M.D. has served as one of our directors since June 2004. Dr. Castaigne is President and CEO of Angiochem Inc., or Angiochem, a position he has held since September 2006. Angiochem leverages its EPiC platform technology to create drugs that cross the blood brain barrier to treat brain diseases. In this capacity, he has advanced multiple clinical and preclinical drug candidates and leads the company's financing and partnering activities. Prior to joining Angiochem, he was COO and CSO of Conjuchem Inc. (TSX: CJB), or Conjuchem, a Montreal-based drug delivery company. Prior to joining Conjuchem in 2000, he was Vice President, World Wide Head of Global R&D at Groupe Fournier SA in France. Before that, he was with Novartis for over 10 years in a variety of international positions, including President and Managing Director for Sandoz Philippines and Director of Medical and R&D for Sandoz in France and as Corporate Vice-President, R&D, Medical and Regulatory in Canada, where he oversaw significant growth in the R & D operation. Earlier in his career, Dr. Castaigne worked for Cilag France (Johnson & Johnson) and Sanofi-Aventis in clinical and regulatory management. He received his M.D. from Paris University in 1975, held the position of Associate Professor of Oncology, Pneumology there in 1978, and received his advanced diploma in Management and Business Administration in 1987 from HEC Paris. We believe Dr. Castaigne's experience working in various pharmaceutical companies as well as his extensive knowledge of all aspects of our preclinical and clinical development plans make him a crucial member of our board of directors.
George B. Abercrombie joined Tranzyme's Board of Directors in September, 2011. He served as President and Chief Executive Officer at Hoffmann-La Roche Inc. from 2001-2009 where he was responsible for leading the North American Pharmaceuticals Operations. He also served as a member of the Roche Pharmaceutical Executive Committee, which was responsible for developing and implementing global strategy for the Pharmaceuticals Division. Before joining Roche, Mr. Abercrombie was Senior Vice President of U.S. commercial operations at Glaxo Wellcome. He joined Glaxo as Vice President and General Manager of the Glaxo Pharmaceuticals Division in 1993 following 10 years at Merck, where he held a broad range of positions in sales, marketing, executive sales management and business development. Mr. Abercrombie currently serves as Chairman of the Board of Brickell Biotech, and was a Director on the Boards of Inspire Pharmaceuticals (recently acquired by Merck) and Ziopharm Oncology. Mr. Abercrombie received a bachelor's degree in pharmacy from the University of North Carolina at Chapel Hill, and earned an M.B.A. from Harvard University.
John H. Johnson has served as the Chairman of our board of directors since November 2010. Mr. Johnson is the president and chief executive officer of Dendreon Corporation, or Dendreon (NASDAQ: DNDN), a position he has held since February 2012. Mr. Johnson has served as a member of Dendreon's board of directors since August 2011. Prior to joining Dendreon, Mr. Johnson was the chief executive officer of Savient Pharmaceuticals, Inc., where he has also served as a member of its board of directors since January 2011. Before joining Savient Pharmaceuticals, Inc., Mr. Johnson served as president of Eli Lilly & Company's Oncology Unit, following the company's 2008 acquisition of Imclone Systems, Inc., where he served as chief executive officer. Prior to joining Imclone, he served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Prior to assuming that role, Mr. Johnson held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp., as well as positions at Pfizer, Inc. Mr. Johnson received his bachelor's degree from East Stroudsburg University of Pennsylvania. He is currently a member of the board of directors for Savient Pharmaceuticals, Inc., and Cempra Pharmaceuticals, Inc.
Here's the attorney firm website for the folks handling the proposed strategic alternative.
http://www.skadden.com/
Better get in while the gettin's good imo. I loaded both barrels the past two days. Onward and upward!
Read Post #1446 that some moderator removed and IHUB reinstated. This tells it all.
Looks like sellers went bye bye.
Nice find! Thanks.
Thanks!
I'm certain that they will listen to you!
Agreed. they are currently trading under cash which would be .503
Maybe we will get some more action and see some green today.
Showed up as a pr on my news feed on Etrade
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Portugal Telecom SGPS SA (NYSE:PT), Patterson-UTI Energy Inc (NASDAQ:PTEN), Swift Transportation Co (NYSE:SWFT), Toyota Motor Corp (NYSE:TM), tw telecom inc (NASDAQ:TWTC), Tranzyme Inc (NASDAQ:TZYM)
Do you know anything about wealthmakers.com? They issued a bullish report yesterday on TZYM and their subscription looks pretty pricey.
I'm with you on that!
Work is a four letter word. Don't you wish we could make a living doing this?
Yes, it was a $300 purchase at 100,000 shares. Wonder who that was.
Level 2 looking good for a very green close. Buyers all line up!